Small molecules are low molecular weight compounds that can easily penetrate cells and interact with specific proteins, enzymes, or signaling pathways. Because of their ability to modulate biological activity with precision, they have become reliable tools in basic research, drug discovery, and the study of disease mechanisms.
One example is Leucine-Rich Repeat Kinase 2 (LRRK2), a kinase implicated in neurodegenerative disease. Mutations in the LRRK2 gene (such as G2019S) are strongly associated with late onset autosomal dominant Parkinson's disease (PD).
Biosensis is proud to offer Leucine-rich repeat serine/theonine-protein kinase 2 (LRRK2-IN-1), a highly potent and selective inhibitor of LRRK2. This compound dynamically blocks both wild-type and G2019S mutant LRRK2 kinase activity with exception efficacy. LRRK2-IN-1 empowers researchers to uncover new insights into Parkinson's disease and explore the role of LRRK2 with confidence.